Related Experiment Video
Updated: Feb 14, 2026
Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
Published on: March 30, 2020
Cell-specific delivery of biologicals: problems, pitfalls and possibilities of antifibrotic compounds in the liver
Klaas Poelstra1, Leonie Beljaars, Barbro N Melgert
1Dept. of Pharmacokinetics, Toxicology & Targeting, University of Groningen, The Netherlands.
Abstract:
Liver fibrosis is a complex disease affecting millions of people world-wide. It involves the activation of several cell types whose activities are tightly controlled by endogenous mediators. No pharmacotherapy is available for this disease, despite the fact that many experimental drugs are very effective in vitro and the liver is easily accessible for most drugs. Our review provides arguments showing that cell-selectivity is essential for most antifibrotics. Several cell-specific drug carriers targeting the key pathogenic liver cells are discussed with special focus on hepatic stellate cells and fibroblast-like cells. Since endogenous mediators represent a powerful set of tools to modify the pathogenic process, this review focuses on these mediators as therapeutics and the problems and pitfalls associated with the use of such biologicals.
Insights
Targeting specific liver cells with drug carriers is crucial for treating liver fibrosis, a condition lacking effective pharmacotherapy. This approach, utilizing endogenous mediators, offers potential therapeutic strategies.
Area of Science:
- Hepatology
- Pharmacology
- Cell Biology
Background:
- Liver fibrosis affects millions globally, characterized by complex cellular activation.
- Current pharmacotherapy options are limited despite promising in vitro drug efficacy.
- Endogenous mediators play a critical role in controlling pathogenic cellular activities.
Purpose of the Study:
- To highlight the essential role of cell-selectivity in antifibrotic therapies.
- To discuss cell-specific drug carriers targeting key pathogenic liver cells, including hepatic stellate cells and fibroblast-like cells.
- To explore the therapeutic potential and challenges of using endogenous mediators for liver fibrosis.
Main Methods:
- Review of existing literature on liver fibrosis pathogenesis.
- Analysis of cell-specific drug delivery systems for antifibrotic agents.
- Evaluation of endogenous mediators as therapeutic tools.
Main Results:
- Cell-selectivity is identified as a critical factor for effective antifibrotic drug action.
- Various cell-specific drug carriers targeting hepatic stellate cells and fibroblast-like cells are presented.
- The potential and limitations of using endogenous mediators as therapeutics are discussed.
Conclusions:
- Targeted drug delivery to specific liver cells is essential for successful antifibrotic therapy.
- Cell-specific drug carriers offer a promising avenue for treating liver fibrosis.
- Further research into endogenous mediators is needed to overcome therapeutic challenges.
Related Concept Videos
01:58Cell Specific Gene Expression
01:58Cell Specific Gene Expression
03:02Organic Compounds
02:38Molecules and Compounds
02:54Coordination Compounds and Nomenclature
01:57What is Conservation Biology?